Cargando…
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
Mutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALK(F1174L) mutation is sensitive to the ALK inhibitor crizotinib only at high doses and mediates acquired resistance to crizotinib in...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226718/ https://www.ncbi.nlm.nih.gov/pubmed/25228590 |
_version_ | 1782343667897335808 |
---|---|
author | Moore, Nathan F. Azarova, Anna M. Bhatnagar, Namrata Ross, Kenneth N. Drake, Lauren E. Frumm, Stacey Liu, Qinsong S. Christie, Amanda L. Sanda, Takaomi Chesler, Louis Kung, Andrew L. Gray, Nathanael S. Stegmaier, Kimberly George, Rani E. |
author_facet | Moore, Nathan F. Azarova, Anna M. Bhatnagar, Namrata Ross, Kenneth N. Drake, Lauren E. Frumm, Stacey Liu, Qinsong S. Christie, Amanda L. Sanda, Takaomi Chesler, Louis Kung, Andrew L. Gray, Nathanael S. Stegmaier, Kimberly George, Rani E. |
author_sort | Moore, Nathan F. |
collection | PubMed |
description | Mutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALK(F1174L) mutation is sensitive to the ALK inhibitor crizotinib only at high doses and mediates acquired resistance to crizotinib in ALK-translocated cancers. We have shown that the combination of crizotinib and an inhibitor of downstream signaling induces a favorable response in transgenic mice bearing ALK(F1174L)/MYCN-positive neuroblastoma. Here, we investigated the molecular basis of this effect and assessed whether a similar strategy would be effective in ALK-mutated tumors lacking MYCN overexpression. We show that in ALK-mutated, MYCN-amplified neuroblastoma cells, crizotinib alone does not affect mTORC1 activity as indicated by persistent RPS6 phosphorylation. Combined treatment with crizotinib and an ATP-competitive mTOR inhibitor abrogated RPS6 phosphorylation, leading to reduced tumor growth and prolonged survival in ALK(F1174L)/MYCN-positive models compared to single agent treatment. By contrast, this combination, while inducing mTORC1 downregulation, caused reciprocal upregulation of PI3K activity in ALK-mutated cells expressing wild-type MYCN. Here, an inhibitor with potency against both mTOR and PI3K was more effective in promoting cytotoxicity when combined with crizotinib. Our findings should enable a more precise selection of molecularly targeted agents for patients with ALK-mutated tumors. |
format | Online Article Text |
id | pubmed-4226718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-42267182014-11-17 Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma Moore, Nathan F. Azarova, Anna M. Bhatnagar, Namrata Ross, Kenneth N. Drake, Lauren E. Frumm, Stacey Liu, Qinsong S. Christie, Amanda L. Sanda, Takaomi Chesler, Louis Kung, Andrew L. Gray, Nathanael S. Stegmaier, Kimberly George, Rani E. Oncotarget Research Paper Mutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALK(F1174L) mutation is sensitive to the ALK inhibitor crizotinib only at high doses and mediates acquired resistance to crizotinib in ALK-translocated cancers. We have shown that the combination of crizotinib and an inhibitor of downstream signaling induces a favorable response in transgenic mice bearing ALK(F1174L)/MYCN-positive neuroblastoma. Here, we investigated the molecular basis of this effect and assessed whether a similar strategy would be effective in ALK-mutated tumors lacking MYCN overexpression. We show that in ALK-mutated, MYCN-amplified neuroblastoma cells, crizotinib alone does not affect mTORC1 activity as indicated by persistent RPS6 phosphorylation. Combined treatment with crizotinib and an ATP-competitive mTOR inhibitor abrogated RPS6 phosphorylation, leading to reduced tumor growth and prolonged survival in ALK(F1174L)/MYCN-positive models compared to single agent treatment. By contrast, this combination, while inducing mTORC1 downregulation, caused reciprocal upregulation of PI3K activity in ALK-mutated cells expressing wild-type MYCN. Here, an inhibitor with potency against both mTOR and PI3K was more effective in promoting cytotoxicity when combined with crizotinib. Our findings should enable a more precise selection of molecularly targeted agents for patients with ALK-mutated tumors. Impact Journals LLC 2014-08-19 /pmc/articles/PMC4226718/ /pubmed/25228590 Text en Copyright: © 2014 Moore et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Moore, Nathan F. Azarova, Anna M. Bhatnagar, Namrata Ross, Kenneth N. Drake, Lauren E. Frumm, Stacey Liu, Qinsong S. Christie, Amanda L. Sanda, Takaomi Chesler, Louis Kung, Andrew L. Gray, Nathanael S. Stegmaier, Kimberly George, Rani E. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma |
title | Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma |
title_full | Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma |
title_fullStr | Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma |
title_full_unstemmed | Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma |
title_short | Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma |
title_sort | molecular rationale for the use of pi3k/akt/mtor pathway inhibitors in combination with crizotinib in alk-mutated neuroblastoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226718/ https://www.ncbi.nlm.nih.gov/pubmed/25228590 |
work_keys_str_mv | AT moorenathanf molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT azarovaannam molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT bhatnagarnamrata molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT rosskennethn molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT drakelaurene molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT frummstacey molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT liuqinsongs molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT christieamandal molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT sandatakaomi molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT cheslerlouis molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT kungandrewl molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT graynathanaels molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT stegmaierkimberly molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma AT georgeranie molecularrationalefortheuseofpi3kaktmtorpathwayinhibitorsincombinationwithcrizotinibinalkmutatedneuroblastoma |